The Trump administration's mass firings at the U.S. Food and Drug Administration have removed employees critical to reviewing ...
As Wilson Sonsini previously reported,1 the U.S. Food and Drug Administration (FDA) had been preparing the industry to comply with the 2024 LDT ...
The U.S. Federal Trade Commission's lawsuit against pharmacy benefit managers (PBMs) over insulin pricing practices will ...
Medical Device Network on MSN19h
‘Fear and uncertainty’ linger over FDA’s future in wake of Trump admin’s layoffsDuring a webinar hosted by NAMSA, experts reflected on what US health agency job cuts could mean for device approvals and ...
More than 102 million U.S. households own a dog or a cat, and thousands more have fish, birds, or reptiles. The resulting pet ...
Given the calls for change, criticism, and ongoing consultations, this article sets out the current status of developments ...
Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon ...
Federal efforts that have successfully driven down rates of youth vaping in recent years may be in peril after dramatic ...
The sudden resignation of Peter Marks, M.D., Ph.D., from the FDA branch that regulates biological products for humans ...
The ruling makes clear that the FDA lacks the legal authority to regulate LDTs, and observers suggest it could also call into question its authority in other areas.
Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback